MMS, a data-focused clinical research organization (CRO) in Canton Township, participated in the creation and release of one of the world’s largest datasets for Alzheimer’s disease, Parkinson’s disease, ALS, and frontotemporal dementia research.
MMS worked on the project with Gates Ventures, owned by Microsoft co-founder Bill Gates; Johnson & Johnson, AD Data Initiative, and the Global Neurodegeneration Proteomics Consortium (GNPC).
“We are honored to support this landmark initiative and are deeply appreciative of the trust that Gates Ventures, AD Data Initiative, and the GNPC have placed in MMS,” says Uma Sharma, founder and CEO of MMS. “Their leadership in tackling the challenges of neurodegenerative conditions through open science and global collaboration is inspiring.
“MMS shares this commitment, and the mission is especially meaningful to our team—making this project a significant milestone. By applying our expertise in harmonizing and anonymizing complex datasets, we’re proud to have contributed to ensuring that this high-impact resource is now securely accessible to the global scientific community.”
MMS supported data intake, harmonization, and anonymization of 250 million unique protein measurements from 35,000 bio samples across 23 international cohorts. The data now is publicly available via the AD Workbench, which is described as one of the world’s largest proteomic datasets for neurodegenerative disease.
MMS provided end-to-end data science support for the initiative, developing and deploying custom tools to streamline the harmonization of diverse proteomic and phenotypic datasets and automate the quality control process, maintaining privacy standards and scientific integrity throughout. The innovations are expected to serve as the foundation for future large-scale data integration efforts in the public domain.
Following the initial cohorts, an upcoming expansion is set to include 13 additional cohorts to further extend the reach and value of this global dataset.
“Neurodegenerative diseases affect tens of millions globally, yet progress in treatment has been slowed by fragmented data and limited biomarker discovery,” says Dr. Farhad Imam, director of health and life sciences at Gates Ventures. “The GNPC Harmonized Dataset marks a major step forward in addressing these challenges by uniting proteomic data at scale.
“This was a technically ambitious effort, and MMS’ expertise and ability to execute on high volume and high complexity data harmonization made them instrumental in delivering this dataset and supporting positive patient impact globally.”
The GNPC welcomes additional data contributions from across the scientific community and continues to advance its mission to improve outcomes for patients with neurodegenerative conditions through shared knowledge and collaboration. The dataset is now publicly available to researchers and institutions working to advance the understanding and treatment of neurodegenerative diseases.
The live dataset is expected to be available for review here in the near future.
For more information on MMS, visit mmsholdings.com.
 in Canton Township, participated in the creation and release of one of the world’s largest datasets for Alzheimer’s disease, Parkinson’s disease, ALS, and frontotemporal dementia research.){kind=link}